文献速递瓣膜病与结构性心脏病

低危主动脉瓣狭窄患者经导管与外科主动脉瓣置换术后六年结局

Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.
PubMed 文献 · J Am Coll Cardiol · 2026-02-16

Evolut低危试验将1414例低危重度主动脉瓣狭窄患者随机分配至TAVR或外科手术,6年时全因死亡或致残性卒中复合终点TAVR组23.3% vs 外科组20.4%(差异2.8%,95%CI -1.9%至7.6%,P=0.43)。6年再干预率TAVR组5.5% vs 外科组3.3%(sHR 1.66,95%CI 0.96-2.86,P=0.07),7年数据TAVR再干预率9.8% vs 外科6.0%(sHR 1.68,95%CI 1.10-2.58,P=0.02),主要由反流再干预增加驱动。

要点

  • TAVR与外科手术6年全因死亡或致残性卒中无显著差异。
  • TAVR组6年再干预率数值更高但未达统计学显著。
  • 7年数据显示TAVR再干预率显著高于外科,反流再干预驱动。

核心结论

  • 低危重度主动脉瓣狭窄患者TAVR与外科手术6年全因死亡或致残性卒中复合终点无显著差异。
  • TAVR组6年和7年再干预率高于外科手术,主要由主动脉瓣反流再干预增加驱动。

研究设计与样本

  • Evolut低危试验为随机对照试验,2016-2019年入组低危重度症状性主动脉瓣狭窄患者。
  • 共1414例患者接受尝试植入,其中TAVR组730例,外科组684例。
  • 预设6年分析采用Kaplan-Meier估计和log-rank检验,并利用数据锁定时可用的7年数据补充分析再干预率。

主要发现

  • 6年全因死亡或致残性卒中复合终点TAVR组23.3%,外科组20.4%(差异2.8%,95%CI -1.9%至7.6%,P=0.43)。
  • 6年全因死亡TAVR组23.3%(95%CI 20.6%-26.4%),外科组20.2%(95%CI 17.4%-23.3%),P=0.24。
  • 6年再干预率TAVR组5.5%,外科组3.3%(sHR 1.66,95%CI 0.96-2.86,P=0.07)。
  • 7年再干预率TAVR组9.8%,外科组6.0%(sHR 1.68,95%CI 1.10-2.58,P=0.02)。
  • 7年反流再干预率TAVR组5.6% vs 外科组1.6%(sHR 3.39,95%CI 1.62-7.07,P<0.001),狭窄再干预率3.6% vs 3.5%(sHR 1.14,95%CI 0.61-2.15,P=0.70)。

临床怎么用

  • 低危主动脉瓣狭窄患者选择TAVR或外科手术时,6年死亡或致残性卒中风险相似。
  • 需关注TAVR术后长期再干预风险,尤其是因主动脉瓣反流导致的再干预。

局限性

  • 7年再干预分析基于数据锁定时部分患者可用的随访数据(TAVR 555例,外科480例),并非全部随机人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Evolut Low Risk trial enrolled patients with severe aortic stenosis at low surgical risk. Annual follow-up is planned for 10 years, evaluating the composite of all-cause mortality or disabling stroke and key secondary endpoints. OBJECTIVES: Our prespecified objective was to report the 6-year clinical outcomes of transcatheter aortic valve replacement (TAVR) vs surgery from the Evolut Low Risk trial. Given an increase in reintervention rates at 6 years, we performed additional analyses in available 7-year data. METHODS: Low-risk patients with severe symptomatic aortic stenosis were randomized to TAVR or surgery from 2016-2019. Prespecified analyses at 6 years included annual follow-up of clinical outcomes reported as Kaplan-Meier estimates with log-rank test. Because the trial enrolled patients over several years, at the time of data lock, a majority of patients had completed 7-year follow-up. Given an increased reintervention rate at 6 years in the TAVR arm, we performed additional analysis of 7-year data available at the time of the database lock. Reintervention rates are reported as cumulative incidence. RESULTS: A total of 1,414 patients underwent an attempted implantation (730 TAVR, 684 surgery). At 6 years, the composite endpoint of all-cause mortality or disabling stroke was 23.3% for TAVR and 20.4% for surgery (difference: 2.8% [95% CI: -1.9% to 7.6%]; P = 0.43). All-cause mortality with vital status sweep at 6 years was 23.3% (95% CI: 20.6%-26.4%) for TAVR and 20.2% (95% CI: 17.4%-23.3%) for surgery (P = 0.24). The reintervention rate at 6 years was 5.5% for TAVR and 3.3% for surgery (sHR: 1.66 [95% CI: 0.96-2.86]; P = 0.07). Using available 7-year follow-up (555 TAVR and 480 surgery), the reintervention rate for TAVR was 9.8% and for surgery was 6.0% (sHR: 1.68 [95% CI: 1.10-2.58]; P = 0.02). In the TAVR and surgery groups, the rate of reintervention for regurgitation was 5.6% vs 1.6% (sHR: 3.39 [95% CI: 1.62-7.07]; P < 0.001) and the rate of reintervention for stenosis was 3.6% vs 3.5% (sHR: 1.14 [95% CI: 0.61-2.15]; P = 0.70). CONCLUSIONS: The 6-year results from the Evolut Low Risk trial show no significant difference in the composite endpoint of all-cause mortality or disabling stroke. At 6 and 7 years, the TAVR arm had a higher reintervention rate compared with surgery, driven by an increased incidence of aortic regurgitation. (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Forrest JK, Yakubov SJ, Deeb GM, et al. Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. J Am Coll Cardiol. 2026. PMID: 41697183. doi:10.1016/j.jacc.2026.02.5063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。